Veru Reports Positive Data From Phase 2b QUALITY Study

(RTTNews) - Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company Monday announced positive topline results from the Phase 2b QUALITY study. The study met its primary goal.

The Phase 2b QUALITY study was designed to evaluate enobosarm compared to placebo in patients more than 60 years of age who are overweight or obese and are receiving Wegovy for weight reduction. Data from the study showed that Patients on enobosarm on average lost 71 percent less lean mass and 27 percent more fat mass than patients receiving Wegovy alone.

"Given the promising topline results from the Phase 2b QUALITY clinical trial where enobosarm treatment preserved lean mass, increased fat loss, improved body composition changes, and prevented decline in stair climb physical function in patients receiving WEGOVY, we plan to meet with FDA to discuss the design of the Phase 3 clinical program," said Mitchell Steiner, M.D., Chairman, President, and Chief Executive Officer of Veru.